

[Chem. Pharm. Bull.]
23(7)1505-1510(1975)]

UDC 547.867.4'853.3'852.2.04

Studies on the Syntheses of N-Heterocyclic Compounds. XXIV.¹⁾
Oxidation of Dihydropyrimido[4,5-d]pyridazine DerivativesAKIO MIYAKE, KATSUMI ITOH, NORIO TADA, YOSHIKAZU OKA,
and SHOJIRO YURUGIMedicinal Research Laboratories, Central Research Division,
Takeda Chemical Industries, Ltd.²⁾

(Received November 18, 1974)

Oxidation of a variety of substituted dihydropyrimido[4,5-d]pyridazine derivatives (I-IV) with 2,3-dichloro-5,6-dicyanoquinone afforded corresponding dehydrogenated aromatic derivatives (V, VII, IX, and X). However, oxidation with potassium ferricyanide, bromine or nitrobenzene gave rise to oxidative elimination of the substituent in addition to normal dehydrogenation, depending upon the variety of the substituent. The substituents readily removed by this novel C-C bond cleavage were benzyl, allyl, *tert*-butyl, cyclohexyl and α -hydroxyalkyl groups.

In the preceding papers we reported the syntheses of substituted dihydropyrimido[4,5-d]pyridazine derivatives (I-IV) by the reaction of organometallic compounds³⁾ or photochemical addition of alcohols and ethers¹⁾ to tetraazapentalene derivatives. Potential diuretic activities exhibited by a wide variety of the obtained compounds as well as by the parent aromatic compounds⁴⁾ led us to assume that 5,8-dimorpholino-2-phenyl-4-substituted pyrimido[4,5-d]pyridazine (V, R=H), which should be obtainable by oxidation of the corresponding dihydro derivative, would also possess diuretic activity. This paper deals with the oxidations of those dihydropyrimido[4,5-d]pyridazine derivatives leading to aromatized compounds.




Chart 1


Oxidation of a series of 5,8-dimorpholino-2-phenyl-4-substituted-3,4-dihydropyrimido[4,5-d]pyridazine (I) with 2,3-dichloro-5,6-dicyanoquinone (DDQ) in benzene afforded desired dehydrogenated products, 5,8-dimorpholino-2-phenyl-4-substituted pyrimido[4,5-d]pyridazine (V), regardless of the variety of 4-substituent. (Table I).

It was found, however, that oxidations with other oxidizing reagents such as potassium ferricyanide, bromine or nitrobenzene gave rise to two types of reaction, normal dehydrogenation to V and oxidative elimination leading to 5,8-dimorpholino-2-phenylpyrimido[4,5-d]pyridazine

1) Part XXIII: A. Miyake, Y. Oka, and S. Yurugi, *Chem. Pharm. Bull.* (Tokyo), **23**, 1500 (1975).

2) Location: Juso, Yodogawa-ku, Osaka.

3) A. Miyake, K. Itoh, N. Tada, Y. Oka, and S. Yurugi, *Chem. Pharm. Bull.* (Tokyo), **23**, 1488 (1975).4) a) S. Yurugi, M. Hieda, T. Fushimi, Y. Kawamatsu, H. Sugihara, M. Tomimoto, *Chem. Pharm. Bull.* (Tokyo), **20**, 1528 (1972); b) S. Yurugi, A. Miyake, and N. Tada, *J. Takeda Res. Lab.*, **32**, 251 (1973).

TABLE I. 5,8-Dimorpholino-2-phenyl-4-substituted pyrimido[4,5-*d*]pyridazine (V)

V	R	Oxidation method ^{a)}	mp (°C)	Yield	Formula	Analysis (%)					
						Calcd.			Found		
						C	H	N	C	H	N
a	C ₆ H ₅ CH ₂	A	163—164	34	C ₂₇ H ₂₆ O ₂ N ₆	69.21	6.02	17.94	69.33	6.02	18.09
b	CH ₃	A	188—190	44	C ₂₁ H ₂₄ O ₂ N ₆	64.27	6.16	21.42	64.30	6.24	21.59
	CH ₃	B	...	64	...	...	...	...	...	...	...
	CH ₃	C	...	8	...	...	...	...	...	...	...
c	CH ₃ CH ₂	A	178—180	51	C ₂₂ H ₂₆ O ₂ N ₆	65.00	6.45	20.68	65.17	6.43	20.57
d	CH ₃ (CH ₂) ₂	A	158—161	49	C ₂₃ H ₂₈ O ₂ N ₆	65.69	6.71	19.99	65.94	6.94	19.70
	CH ₃ (CH ₂) ₂	B	...	74	...	...	...	...	...	...	...
e	(CH ₃) ₂ CH	A	191—192	47	C ₂₃ H ₂₈ O ₂ N ₆	65.69	6.71	19.99	65.89	6.70	19.94
f	CH ₃ (CH ₂) ₃	A	128—129	50	C ₂₄ H ₃₀ O ₂ N ₆	66.34	6.96	19.34	66.22	6.97	19.25
g	(CH ₃) ₂ CHCH ₂	A	167—169	46	C ₂₄ H ₃₀ O ₂ N ₆	66.34	6.96	19.34	66.46	7.03	19.04
h	(CH ₃) ₂ CH(CH ₂) ₂	A	157—159	55	C ₂₅ H ₃₂ O ₂ N ₆	66.94	7.19	18.74	67.16	7.20	18.39
i	CH ₃ (CH ₂) ₅	A	118—119	50	C ₂₆ H ₃₄ O ₂ N ₆	67.50	7.41	18.17	67.54	7.51	18.06
j		A	221—227	50	C ₂₆ H ₃₂ O ₂ N ₆	67.80	7.00	18.25	67.70	6.99	18.17
		B	...	18	...	...	...	...	...	...	...
k	C ₆ H ₅ (CH ₂) ₂	A	189—191	58	C ₂₈ H ₃₀ O ₂ N ₆	69.69	6.27	17.42	69.64	6.24	17.35
l	C ₆ H ₅	A	229—230	54	C ₂₆ H ₂₆ O ₂ N ₆	68.70	5.77	18.48	68.72	5.77	18.47
m		A	254—256	33	C ₂₅ H ₂₅ O ₂ N ₇	65.93	5.53	21.53	65.92	5.41	21.67
n		A	224—226	59	C ₂₄ H ₂₄ O ₂ N ₆ S	62.60	5.25	18.25	62.59	5.22	18.50
o	HOCH ₂	A	190—192	43	C ₂₁ H ₂₄ O ₃ N ₆	61.75	5.92	20.58	61.88	6.00	20.33
p		B	202—204	85	C ₂₄ H ₂₈ O ₄ N ₆	62.05	6.08	18.09	61.97	6.15	17.88

a) A: oxidation with DDQ B: oxidation with K₃Fe(CN)₆-KOH C: oxidation with nitrobenzene

(VI), depending upon the variety of 4-substituent. Thus, the oxidation of 4-benzyl derivative (Ia) (I, R=C₆H₅CH₂) with aqueous potassium ferricyanide in alkaline solution gave VI with oxidative liberation of the benzyl group as benzaldehyde. Such an abnormal oxidative elimination was also observed when 4-substituent in I was allyl, *tert*-butyl, cyclohexyl or α -hydroxyalkyl group (Table II). On the other hand, other 4-alkyl, aryl and aralkyl derivatives as well as

4-(1,4-dioxan-2-yl) derivative (I, R=) gave only normal dehydrogenated product (V).

Since dehydrogenated 4-benzyl derivative (V, R=C₆H₅CH₂) proved to be stable to the ferricyanide oxidation, it is clear that the elimination occurred prior to the aromatization. Although we have no evidence at present as to whether those ferricyanide oxidations proceed *via* ionic or radical mechanism, it seems that the feasibility of the oxidative elimination reaction is closely related with the stability of carbonium ion or radical on the eliminated species. The oxidative elimination of α -hydroxyalkyl group in I resembles the ferricyanide oxidation of

α -hydroxyethylthiamine (HET) to thiochrome liberating acetaldehyde,⁵⁾ though such carbon-carbon bond cleavage is quite rare in literatures.





TABLE II. Formation of 5,8-Dimorpholino-2-phenylpyrimido[4,5-*d*]pyridazine (VI) by Oxidative Elimination of I


R in I	Reaction condition		VI Yield (%)
	Reagent	Solvent	
$\text{C}_6\text{H}_5\text{CH}_2$	$\text{Br}_2\text{-AcONa}$	AcOH	33
$\text{C}_6\text{H}_5\text{CH}_2$	nitrobenzene	—	41
$\text{C}_6\text{H}_5\text{CH}_2$	$\text{K}_3\text{Fe}(\text{CN})_6\text{-KOH}$	$\text{C}_6\text{H}_6\text{-H}_2\text{O}$	85
$(\text{CH}_3)_3\text{C}$	$\text{K}_3\text{Fe}(\text{CN})_6\text{-KOH}$	$\text{C}_6\text{H}_6\text{-H}_2\text{O}$	66
H	$\text{K}_3\text{Fe}(\text{CN})_6\text{-KOH}$	$\text{C}_6\text{H}_6\text{-H}_2\text{O}$	26
$\text{CH}_2=\text{CH-CH}_2$	$\text{K}_3\text{Fe}(\text{CN})_6\text{-KOH}$	$\text{C}_6\text{H}_6\text{-H}_2\text{O}$	29
HOCH_2	$\text{K}_3\text{Fe}(\text{CN})_6\text{-KOH}$	$\text{C}_6\text{H}_6\text{-H}_2\text{O}$	74
$\text{CH}_3\text{CH}(\text{OH})$	$\text{K}_3\text{Fe}(\text{CN})_6\text{-KOH}$	$\text{C}_6\text{H}_6\text{-H}_2\text{O}$	66
$\text{C}_6\text{H}_5\text{CH}(\text{OH})$	$\text{K}_3\text{Fe}(\text{CN})_6\text{-KOH}$	$\text{C}_6\text{H}_6\text{-H}_2\text{O}$	51
$(\text{CH}_3)_2\text{C}(\text{OH})$	$\text{K}_3\text{Fe}(\text{CN})_6\text{-KOH}$	$\text{C}_6\text{H}_6\text{-H}_2\text{O}$	74

Similar results were obtained by the oxidations of II, III, and IV. Thus, oxidation of 4,8-dibenzyl-5-morpholino-2-phenyl-3,4-dihydropyrimido[4,5-*d*]pyridazine (II, $\text{R}=\text{C}_6\text{H}_5\text{CH}_2$) with DDQ gave dehydrogenated VIIa, while the oxidation with potassium ferricyanide yielded VIII, in which only the benzyl group at 4 position was eliminated. A series of VII obtained by DDQ oxidations of corresponding II is listed in Table III. Ferricyanide oxidation of 4-benzyl-5,7-dimorpholino-2-phenyl-3,4-dihydropyrimido[4,5-*d*]pyrimidine (III, $\text{R}=\text{C}_6\text{H}_5\text{CH}_2$) resulted in oxidative elimination to give 5,7-dimorpholino-2-phenylpyrimido[4,5-*d*]pyrimidine

5) H. Asakawa, E. Imamiya, and H. Hirano, *J. Takeda Res. Lab.*, **30**, 705 (1971).

TABLE III. 5-Morpholino-2-phenyl-4,8-disubstituted pyrimido[4,5-*d*]pyridazine (VII)

VII	R	Yield (%)	mp (°C)	Formula	Analysis (%)					
					Calcd.			Found		
					C	H	N	C	H	N
a	C ₆ H ₅ CH ₂	33	170—172	C ₃₀ H ₂₇ ON ₅ ·C ₆ H ₅ O ₆ N ₃	61.56	4.31	15.94	61.51	3.82	16.02
b	CH ₃ (CH ₂) ₂	34	207—210	C ₂₂ H ₂₇ ON ₅	70.00	7.21	18.55	70.00	7.28	18.58
c	CH ₃ (CH ₂) ₃	25	70—73	C ₂₄ H ₃₁ ON ₅	71.08	7.71	17.27	71.00	7.93	17.25
d	(CH ₃) ₂ CH(CH ₂) ₂	15	155—158	C ₂₆ H ₃₅ ON ₅ ·HCl	66.49	7.72	14.90	66.47	7.93	14.89
e	(CH ₃) ₂ CH	34	143—144	C ₂₂ H ₂₇ ON ₅	70.00	7.21	18.55	69.54	7.51	18.33
f	CH ₃ (CH ₂) ₅	32	154—155	C ₂₈ H ₃₉ ON ₅ ·HCl	67.52	8.09	14.06	67.44	8.07	13.98
g	C ₆ H ₅ (CH ₂) ₂	42	202—204	C ₃₂ H ₃₁ ON ₅	76.02	6.23	13.96	76.62	6.14	13.92
h		45	197—200	C ₂₈ H ₃₅ ON ₅	73.49	7.71	15.31	73.27	8.13	15.29

TABLE IV. 5,8-Dimorpholino-2-phenyl-3-substituted pyrazino[2,3-*d*]pyridazine (X)

X	R	Yield	mp (°C)	Formula	Analysis (%)					
					Calcd.			Found		
					C	H	N	C	H	N
b	CH ₃	85	165—168	C ₂₁ H ₂₄ O ₂ N ₆	64.27	6.16	21.42	64.31	5.89	21.19
c	CH ₃ CH ₂	39	153—156	C ₂₂ H ₂₆ O ₂ N ₆	65.00	6.45	20.68	64.69	6.43	20.17
d	C ₆ H ₅	66	223—226	C ₂₆ H ₂₆ O ₂ N ₆	68.70	5.77	18.49	68.93	5.65	18.34
e		90	210—212	C ₂₄ H ₂₈ O ₄ N ₆	62.05	6.08	18.09	61.97	6.15	17.88

(IXa), while 4-ethyl derivogenative (III, R=C₂H₅) was dehydrogenated to IXb in 95% yield under the same condition. Similarly, 5,8-dimorpholino-2-phenylpyrazino[2,3-*d*]pyridazine (Xa)⁶⁾ was obtained by the ferricyanide oxidation of 3-benzyl or 3-hydroxymethyl-5,8-dimorpholino-2-phenyl-3,4-dihydropyrazino[2,3-*d*]pyridazine (IV, R=C₆H₅CH₂, or CH₂OH). On the other hand, normal dehydrogenated product (Xb—e) was obtained when the 4-substituent was methyl, ethyl, phenyl, or 1,4-dioxan-2-yl group.

6) S. Yurugi and M. Hieda, *Yakugaku Zasshi*, **92**, 1322 (1972).




Chart 3

Contrary to our assumption, 5,8-dimorpholino-2-phenyl-4-substituted pyrimido[4,5-*d*]-pyridazines (V, R≠H) showed virtually no diuretic activity. The result is somewhat interesting in view of the fact that 4-unsubstituted derivative (V, R=H) and many of the 4-substituted-3,4-dihydroderivatives (II) are potent diuretics.

Experimental⁷⁾

5,8-Dimorpholino-2-phenyl-4-substituted pyrimido[4,5-*d*]pyridazine (V) (Table I)—a) To a stirred solution of I³) (1.5 mmole) in C₆H₆ (100 ml) was added a solution of DDQ (1.7 mmole) in C₆H₆ (50 ml) at room temperature. After 0.5—1 hr the reaction mixture was purified by column chromatography on silica gel to give crude product, which was recrystallized from ether or MeOH to give V.

b) To a stirred solution of I (0.2 mmole) in C_6H_6 (200 ml) was added a solution of $K_3Fe(CN)_6$ (6.0 g) in H_2O (40 ml). Then a solution of KOH (3.0 g) in H_2O (7 ml) was added to the reaction mixture at room temperature. After 5–10 hr the organic layer was separated, washed with H_2O , dried over Na_2SO_4 and evaporated *in vacuo*. The residue was recrystallized from petroleum ether or ether to give V.

c) A solution of 4-methyl-5,8-dimorpholino-2-phenyl-3,4-dihydropyrimido[4,5-*d*]pyridazine (0.5 g) in nitrobenzene (20 ml) was refluxed for 30 hr. The reaction mixture was chromatographed on silica gel. Elution with C₆H₆-acetone (3:1) gave Vb, mp 188—190°.

5,8-Dimorpholino-2-phenylpyrimido[4,5-*d*]pyridazine (VI) (Table II)—a) To a stirred solution of Ia³ (0.2 mmole) in C₆H₆ (40 ml) was added a solution of K₃Fe(CN)₆ (6.0 g) in H₂O (40 ml). A solution of KOH (3.0 g) in H₂O (7 ml) was added to the reaction mixture at room temperature. After 5 hr the organic layer was separated, washed with H₂O and dried over Na₂SO₄. After removal of the solvent, the residue was purified by column chromatography on silica gel eluted with C₆H₆ to give benzaldehyde (0.11 g, 51%) which showed complete identity with an authentic sample in infrared (IR) spectrum. Further elution with C₆H₆-acetone (4:1) gave VI. Recrystallization from ether gave yellow needles, mp 180–182°, which showed complete identity with an authentic sample^{4a} in the mixed melting point and IR spectrum.

b) A solution of Ia (1.0 g) in nitrobenzene (50 ml) was refluxed for 8 hr. The reaction mixture was dissolved in C₆H₆ (100 ml) and purified by column chromatography on silica gel eluted with C₆H₆-acetone (9:1) to give VI (0.37 g, 41%).

c) To a solution of Ia (0.9 g) and AcONa (0.5 g) in AcOH (20 ml) was added dropwise 0.5 g of Br₂ with stirring at room temperature. After 3 hr the separated crystalline products were collected by filtration and dissolved in aqueous MeOH. The resulting solution was made alkaline with NaHCO₃. The separated crystals were collected by filtration, washed with H₂O, and recrystallized from EtOH to give VI (0.25 g, 33%).

5-Morpholino-2-phenyl-4,8-disubstituted pyrimido[4,5-*d*]pyridazine (VII) (Table III)—To a solution of II (2 mmole) in C_6H_6 (100 ml), was added a solution of DDQ (2.2 mmole) in C_6H_6 (50 ml) with stirring. After 0.5—1 hr, the reaction mixture was purified by column chromatography on silica gel eluted with C_6H_6 —acetone (9:1) to give VII, which was recrystallized from petroleum ether or ether. In the case that VII was an oil, it was led to hydrochloride.

8-Benzyl-5-morpholino-2-phenylpyrimido[4,5-*d*]pyridazine (VIII)—To a stirred solution of 4,8-dibenzyl-5-morpholino-2-phenyl-3,4-dihydropyrimido[4,5-*d*]pyridazine (II)³ (0.5 g) in C₆H₆ (100 ml) was added a solution of K₃Fe(CN)₆ (0.6 g) in H₂O (40 ml). Then a solution of KOH (3.0 g) in H₂O (7 ml) was added to

7) All melting points were taken on a Kofler-type hot-stage apparatus (Yanagimoto Co.) and are uncorrected. Nuclear magnetic resonance (NMR) spectra were measured on Varian HA-100 or A-60 high resolution spectrometers.

the reaction mixture. After 10 hr the organic layer was separated, washed with H_2O , and dried over Na_2SO_4 . After removal of the solvent, the residue was purified by column chromatography on silica gel eluted with C_6H_6 -acetone (9:1) to give VIII (0.3 g, 74%), yellow needles, mp 139–140°. *Anal.* Calcd. for $\text{C}_{23}\text{H}_{21}\text{ON}_5$: C, 72.04; H, 5.52; N, 18.27. Found: C, 72.04; H, 5.21; N, 18.17. NMR (in CDCl_3) τ : 6.30–6.44 (4H, m, morpholine), 6.03–6.28 (4H, m, morpholine), 5.26 (2H, s, $\text{CH}_2\text{-C}_6\text{H}_5$), 2.40–2.90 (8H, m, phenyl), 1.38–1.50 (2H, m, phenyl), 0.50 (1H, s, $\text{C}_4\text{-H}$).

5,7-Dimorpholino-2-phenylpyrimido[4,5-*d*]pyrimidine (IXa)—To a stirred solution of 4-benzyl-5,7-dimorpholino-2-phenyl-3,4-dihydropyrimido[4,5-*d*]pyrimidine (IIIa)³⁾ (0.47 g) in C_6H_6 (40 ml) was added a solution of $\text{K}_3\text{Fe}(\text{CN})_6$ (7.5 g) in H_2O (40 ml). Then a solution of KOH (3.8 g) in H_2O (10 ml) was added to the reaction mixture at room temperature. After 14 hr the organic layer was separated, washed with H_2O , and dried over Na_2SO_4 . After removal of the solvent, the residue was recrystallized from C_6H_6 -ether to give IXa (0.2 g, 53%) mp 247–249°, which showed complete identity with an authentic sample^{4b)} in the mixed melting point and IR spectrum.

4-Ethyl-5,7-dimorpholino-2-phenylpyrimido[4,5-*d*]pyrimidine (IXb)—To a stirred solution of 4-ethyl-5,7-dimorpholino-2-phenyl-3,4-dihydropyrimido[4,5-*d*]pyrimidine (IIIb)³⁾ (0.2 g) in C_6H_6 (40 ml) was added a solution of $\text{K}_3\text{Fe}(\text{CN})_6$ (4.5 g) in H_2O (30 ml). Then a solution of KOH (2.0 g) in H_2O (5 ml) was added to the reaction mixture at room temperature. After 10 hr the organic layer was separated, washed with H_2O , dried over Na_2SO_4 and evaporated *in vacuo*. The residue was recrystallized from ether to give IXb (0.19 g, 95%), mp 170–173°. *Anal.* Calcd. for $\text{C}_{22}\text{H}_{26}\text{O}_2\text{N}_6$: C, 65.00; H, 6.45; N, 20.68. Found: C, 64.89; H, 6.43; N, 20.61. NMR (in CDCl_3) τ : 8.65 (3H, t, $J=7.2$ Hz, CH_3), 6.88 (2H, q, $J=7.2$ Hz, $\text{CH}_2\text{-CH}_3$), 5.90–6.50 (16H, m, morpholine), 2.44–2.64 (3H, m, phenyl), 1.28–1.52 (2H, m, phenyl).

5,8-Dimorpholino-2-phenylpyrazino[2,3-*d*]pyridazine (Xa)—a) To a stirred solution of 3-benzyl-5,8-dimorpholino-2-phenyl-3,4-dihydropyrazino[2,3-*d*]pyridazine (IV)³⁾ (0.47 g) in C_6H_6 (80 ml) was added a solution of $\text{K}_3\text{Fe}(\text{CN})_6$ (3.0 g) in H_2O (20 ml). Then a solution of KOH (1.5 g) in H_2O (3.5 ml) was added to the reaction mixture at room temperature. After 3 hr the organic layer was separated, washed with H_2O , dried over Na_2SO_4 and evaporated *in vacuo*. The residue was recrystallized from C_6H_6 -ether to give Xa (0.2 g, 53%) as red prisms, mp 191–192°, which showed complete identity with an authentic sample⁶⁾ in the mixed melting point and IR spectrum.

b) To a stirred solution of 3-hydroxymethyl-5,8-dimorpholino-2-phenyl-3,4-dihydropyrazino[2,3-*d*]pyridazine (IV)¹⁾ (0.2 g) in C_6H_6 (20 ml) was added a solution of $\text{K}_3\text{Fe}(\text{CN})_6$ (3.0 g) in H_2O (20 ml). Then a solution of KOH (2.0 g) in H_2O (8 ml) was added to the reaction mixture at room temperature. After 2 hr the organic layer was separated, washed with H_2O , dried over Na_2SO_4 and evaporated *in vacuo*. The residue was recrystallized from C_6H_6 -ether to give Xa (0.17 g, 85%).

5,8-Dimorpholino-2-phenyl-3-substituted pyrazino[2,3-*d*]pyridazine (Xb-e)—To a solution of 5,8-dimorpholino-2-phenyl-3-substituted-3,4-dihydropyrazino[2,3-*d*]pyridazine (IV)^{1,3)} (0.5 mmole) in C_6H_6 (40 ml) was added a solution of $\text{K}_3\text{Fe}(\text{CN})_6$ (1.5 g) in H_2O (10 ml). Then a solution of KOH (0.7 g) in H_2O (3 ml) was added to the reaction mixture at room temperature. After 1–4 hr the organic layer was separated, washed with H_2O , dried over Na_2SO_4 and evaporated *in vacuo*. The residue was recrystallized from ether to give X.

Acknowledgement The authors express their deep gratitude to Dr. S. Tatsuoka and Dr. E. Ohmura for their encouragement throughout this work. Thanks are due to the members who undertook the elemental analysis and NMR measurements.